The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C

Ekkaphon Metharom, Peter Galettis, Susan Manners, Maria Jelinek, Winston Liauw, Paul L De Souza, Janelle M Hoskins, M. Links*

*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

9 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C'. Together they form a unique fingerprint.

Medicine & Life Sciences